Announcements Trials

Conditions

Genitourinary 2Thoracic 2Myeloid 1Other 1

Drug Classes

Bcr-Abl inhibitor 7IDH inhibitor 6DNA methyltransferase inhibitor 5FLT3 inhibitor 3KMT2A inhibitor 3Anthracycline 2Anti-CD33 ADC 2IL-3 fused immunotoxin 2STAMP inhibitor 2Alkylating agent 1Anti-IFNg 1BRAF inhibitor 1Bcl-2 inhibitor 1FGFR inhibitor 1Hedgehog pathway inhibitor 1JAK inhibitor 1PDGFR inhibitor 1Purine analog 1Pyrimidine analog 1TGF-beta inhibitor 1Telomerase inhibitor 1
Alkylating agent × Myeloid × Clear all

1 Announcement

2025-02-06

FDA approves treosulfan with fludarabine as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS

Drugs
Grafapex (treosulfan) · Alkylating agent, fludarabine · Purine analog
Condition
Myeloid
Data powered by HemOnc (CC BY 4.0) Colophon âš¡